Complete restoration of phenylalanine oxidation in phenylketonuria mouse by a self-complementary adeno-associated virus vector

Journal of Gene Medicine

Volumn 13, Issue 2, 2011, Pages 114-122

  Yagi, Hiroya ^a,b   Ogura, Tsuyoshi ^b   Mizukami, Hiroaki ^a   Urabe, Masashi ^a   Hamada, Hiromi ^b   Yoshikawa, Hiroyuki ^b   Ozawa, Keiya ^a   Kume, Akihiro ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Adeno associated virus; Gene therapy; Phenylalanine oxidation; Phenylketonuria

Indexed keywords

NANOPARTICLE; PARVOVIRUS VECTOR; PHENYLALANINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIPLOIDY; FEMALE; FLUOROMETRY; GENE DOSAGE; GENE EXPRESSION; IN VIVO STUDY; LIVER; MALE; MOUSE; NONHUMAN; OXIDATION; PHENYLKETONURIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; UREA BREATH TEST;

ANIMALS; DEPENDOVIRUS; FEMALE; GENE ORDER; GENE THERAPY; GENETIC VECTORS; HEK293 CELLS; HUMANS; LIVER; MALE; MICE; OXIDATION-REDUCTION; PHENYLALANINE; PHENYLALANINE HYDROXYLASE; PHENYLKETONURIAS; TIME FACTORS; TRANSDUCTION, GENETIC;

ADENO-ASSOCIATED VIRUS; ANIMALIA; MUS;

EID: 79952644629     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1543     Document Type: Article

References (41)

1. Scriver CR, Kaufman S. Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. In The Metabolic and Molecular Bases of Inherited Disease, Scriver CR, Beaudet AL, Sly WS, Valle D (eds). McGraw-Hill: New York, NY, 2001; 1667-1724.
2. Eisensmith RC, Woo SLC. Gene therapy for phenylketonuria. Eur J Pediatr 1996; 155: S16-S19.
3. Thöny B. Long-term correction of murine phenylketonuria by viral gene transfer: liver versus muscle. J Inherit Metab Dis 2010; 33: 677-680.
4. Shedlovsky A, McDonald JD, Symula D, Dove WF. Mouse models of human phenylketonuria. Genetics 1993; 134: 1205-1210.
5. McDonald JD, Charlton CK. Characterization of mutations at the mouse phenylalanine hydroxylase locus. Genomics 1997; 39: 402-405.
6. Laipis PJ, Charron C, Ross K, et al. Long-term correction of phenylketonuria in an animal model by recombinant AAV-based gene therapy. J lnherit Metab Dis 2002; 25: 615-616.
7. Mochizuki S, Mizukami H, Ogura T, et al. Long-term correction of hyperphenylalaninemia by AAV-mediated gene transfer leads to behavioral recovery in phenylketonuria mice. Gene Ther 2004; 11: 1081-1086.
8. Oh H, Park E, Kang S, Jo I, Jung S. Long-term enzymatic and phenotypic correction in the phenylketonuria mouse model by adeno-associated virus vector-mediated gene transfer. Pediatr Res 2004; 56: 278-284.
9. Harding CO, Gillingham MB, Hamman K, et al. Complete correction of hyperphenylalaninemia following liver-directed, recombinant AAV2/8 vector-mediated gene therapy in murine phenylketonuria. Gene Ther 2006; 13: 457-462.
10. Ding Z, Georgiev P, Thöny B. Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer. Gene Ther 2006; 13: 587-593.
11. Davidoff AM, Ng CYC, Zhou J, Spence Y, Nathwani AC. Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. Blood 2003; 102: 480-488.
12. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002; 99: 11854-11859.
13. Davidoff AM, Gray JT, Ng CYC, et al. Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5 and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol Ther 2005; 11: 875-888.
14. Wang L, Calcedo R, Nichols TC, et al. Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. Blood 2005; 105: 3079-3086.
15. Russell DW, Kay MA. Adeno-associated virus vectors and hematology. Blood 1999; 94: 864-874.
16. Nakai H, Storm TA, Kay MA. Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo. J Virol 2000; 74: 9451-9463.
17. McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 2001; 8: 1248-1254.
18. McCarty DM, Fu H, Monahan PE, Toulson CE, Naik P, Samulski RJ. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 2003; 10: 2112-2118.
19. Wang Z, Ma H-I, Li J, Sun L, Zhang J, Xiao X. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther 2003; 10: 2105-2111.
20. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991; 108: 193-200.
21. Nathwani AC, Gray JT, Ng CYC, et al. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood 2006; 107: 2653-2661.
22. Matsushita T, Elliger S, Elliger C, et al. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther 1998; 5: 938-945.
23. Okada T, Nomoto T, Shimazaki K, et al. Adeno-associated virus vectors for gene transfer to the brain. Methods 2002; 28: 237-247.
24. Okada T, Nomoto T, Yoshioka T, et al. Large-scale production of recombinant viruses by use of a large culture vessel with active gassing. Hum Gene Ther 2005; 16: 1212-1218.
25. Ishiwata A, Mimuro J, Mizukami H, et al. Liver-restricted expression of the canine factor VIII gene facilitates prevention of inhibitor formation in factor VIII-deficient mice. J Gene Med 2009; 11: 1020-1029.
26. Lock M, McGorray S, Auricchio A, et al. Characterization of a recombinant adeno-associated virus type 2 reference standard material. Hum Gene Ther 2010; 21: 1273-1285.
27. Kure S, Sato K, Fujii K, et al. Wild-type phenylalanine hydroxylase activity is enhanced by tetrahydrobiopterin supplementation in vivo: an implication for therapeutic basis of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Mol Genet Metab 2004; 83: 150-156.
28. Mochizuki S, Mizukami H, Kume A, et al. Adeno-associated virus (AAV) vector-mediated liver- and muscle-directed transgene expression using various kinds of promoters and serotypes. Gene Ther Mol Biol 2004; 8: 9-18.
29. Ogura T, Mizukami H, Zhang YY, et al. Tissue distribution of expression using AAV8-based vectors after intramuscular injection and other routes of delivery. Mol Ther 2005; 11: S334.
30. Ogura T, Mizukami H, Mimuro J, et al. Utility of intraperitoneal administration as a route of AAV serotype 5 vector-mediated neonatal gene transfer. J Gene Med 2006; 8: 990-997.
31. Fang B, Eisensmith RC, Li XHC, et al. Gene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer. Gene Ther 1994; 1: 247-254.
32. Pañeda A, Vanrell L, Mauleon I, et al. Effect of adeno-associated virus serotype and genomic structure on liver transduction and biodistribution in mice of both genders. Hum Gene Ther 2009; 20: 908-917.
33. Vaessen SFC, Veldman RJ, Comijn EM, et al. AAV gene therapy as a means to increase apolipoprotein (Apo) A-I and high-density lipoprotein-cholesterol levels: correction of murine ApoA-I deficiency. J Gene Med 2009; 11: 697-707.
34. Wu Z, Sun J, Zhang T, et al. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol Ther 2008; 16: 280-289.
35. Nathwani AC, Cochrane M, McIntosh J, et al. Enhancing transduction of the liver by adeno-associated viral vectors. Gene Ther 2009; 16: 60-69.
36. Nakai H, Fues S, Storm TA, Muramatsu S, Nara Y, Kay MA. Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J Virol 2005; 79: 214-224.
37. Nakai H, Yant SR, Storm TA, Fuess S, Meuse L, Kay MA. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol 2001; 75: 6969-6976.
38. Calos MP. The ΦC31 integrase system for gene therapy. Curr Gene Ther 2006; 6: 633-645.
39. Ding Z, Harding CO, Rebuffat A, Elzaouk L, Wolff JA, Thöny B. Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system. Mol Ther 2008; 16: 673-681.
40. Rebuffat A, Harding CO, Ding Z, Thöny B. Comparison of adeno-associated virus pseudotype 1, 2, and 8 vectors administered by intramuscular injection in the treatment of murine phenylketonuria. Hum Gene Ther 2010; 21: 463-477.
41. Nathwani AC, Rosales C, McIntoh J, et al. Early clinical trial results following administration of a low dose of a novel self complementary adeno-associated viral vector encoding human factor ix in two subjects with severe haemophilia B. Hum Gene Ther 2010; 21: 1362.